Show simple item record

dc.contributor.authorHorsley, Laura
dc.contributor.authorCummings, Jeffrey
dc.contributor.authorMiddleton, M
dc.contributor.authorWard, Timothy H
dc.contributor.authorBacken, Alison C
dc.contributor.authorClamp, Andrew R
dc.contributor.authorDawson, Martin J
dc.contributor.authorFarmer, H
dc.contributor.authorFisher, N
dc.contributor.authorHalbert, G
dc.contributor.authorHalford, S
dc.contributor.authorHarris, A
dc.contributor.authorHasan, Jurjees
dc.contributor.authorHogg, P
dc.contributor.authorKumaran, Gireesh C
dc.contributor.authorLittle, R
dc.contributor.authorParker, G
dc.contributor.authorPotter, Paula
dc.contributor.authorSaunders, Mark P
dc.contributor.authorRoberts, C
dc.contributor.authorShaw, Danielle
dc.contributor.authorSmith, Nigel K
dc.contributor.authorSmythe, J
dc.contributor.authorTaylor, A
dc.contributor.authorTurner, H
dc.contributor.authorWatson, Y
dc.contributor.authorDive, Caroline
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2013-12-20T09:59:49Zen
dc.date.available2013-12-20T09:59:49Zen
dc.date.issued2013-12en
dc.identifier.citationA phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. 2013, 72 (6):1343-52 Cancer Chemother Pharmacolen
dc.identifier.issn1432-0843en
dc.identifier.pmid24141375en
dc.identifier.doi10.1007/s00280-013-2320-9en
dc.identifier.urihttp://hdl.handle.net/10541/308799en
dc.description.abstract4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is a water-soluble mitochondrial toxin that binds to adenine nucleotide translocase in the inner mitochondrial membrane, thereby targeting cell proliferation. This phase 1 study investigated safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics (PK) of GSAO as a daily 1-h infusion for 5 days a week for 2 weeks in every three. Pharmacodynamics of GSAO was evaluated by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and circulating markers of angiogenesis.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer chemotherapy and pharmacologyen
dc.titleA phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.en
dc.typeArticleen
dc.contributor.departmentInstitute for Cancer Studies Christie Hospital NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstract4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is a water-soluble mitochondrial toxin that binds to adenine nucleotide translocase in the inner mitochondrial membrane, thereby targeting cell proliferation. This phase 1 study investigated safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics (PK) of GSAO as a daily 1-h infusion for 5 days a week for 2 weeks in every three. Pharmacodynamics of GSAO was evaluated by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and circulating markers of angiogenesis.


This item appears in the following Collection(s)

Show simple item record